Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473405 | 0.84 | FAAH (0.53) | GPR119FAAHKDM4EPKM | |
| SCHEMBL4480416 | 0.80 | GPR119 (0.57) | GPR119FAAHKDM4EPKMUSP30 | |
| SCHEMBL9023012 | 0.79 | GPR119 (0.53) | GPR119FAAHKDM4EPKMUSP30 | |
| SCHEMBL4330385 | 0.78 | GPR119 (0.57) | GPR119FAAHKDM4EPKM | |
| SCHEMBL4768721 | 0.78 | GPR119 (0.62) | GPR119KDM4EPKMUSP30 | |
| SCHEMBL14597290 | 0.76 | GPR119 (0.53) | GPR119FAAHKDM4EPKM | |
| SCHEMBL29566603 | 0.74 | GPR119 (0.61) | GPR119FAAHKDM4EPKM | |
| SCHEMBL1088570 | 0.74 | GPR119 (0.61) | GPR119FAAHKDM4EPKM | |
| SCHEMBL389003 | 0.74 | FAAH (0.53) | GPR119FAAHKDM4EPKM | |
| SCHEMBL13391117 | 0.73 | GPR119 (0.60) | GPR119FAAHKDM4EPKMUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622605-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, GTF3C4, POLRMT | GPR119 3573/4885FAAH 3276/4885KDM4E 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.